The detailed dive history may be necessary in these cases.In terms of barotrauma the diagnostic workup for the affected individual could include the following:
Laboratory:
Creatine kinase (CPK) level: Increases in CPK levels indicate tissue damage associated with decompression sickness. Complete blood count (CBC)
Arterial blood gas (ABG) determinationImaging:
Chest radiography can show pneumothorax, and is indicated if there is chest discomfort or breathing difficulty
Computed tomography (CT) scans and magnetic resonance imaging (MRI) may be indicated when there is severe headache or severe back pain after diving. CT is the most sensitive method to evaluate for pneumothorax. It can be used where barotrauma-related pneumothorax is suspected and chest radiograph findings are negative. Echocardiography can be used to detect the number and size of gas bubbles in the right side of the heart. Ear barotrauma
Barotrauma can affect the external, middle, or inner ear. Middle ear barotrauma (MEBT) is the most common diving injury, being experienced by between 10% and 30% of divers and is due to insufficient equilibration of the middle ear. External ear barotrauma may occur  if air is trapped in the external auditory canal. Diagnosis of middle and external ear barotraume is relatively simple, as the damage is usually visible if severe enough to require intervention. External auditory canal
Barotrauma can occur in the external auditory canal if it is blocked by cerumen, exostoses, a tight-fitting diving suit hood or earplugs, which create an airtight, air-filled space between the eardrum and the blockage.
In July of that year AstraZeneca licensed tralokinumab to Leo Pharma for skin diseases.A phase IIb study of tralokinumab found that treatment was associated with early and sustained improvements in atopic dermatitis symptoms and tralokinumab had an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with atopic dermatitis.On 15 June 2017, Leo Pharma announced that they were starting phase III clinical trials with tralokinumab in atopic dermatitis. Society and culture
Legal status
On 22 April 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Adtralza, intended for the treatment of moderate‑to‑severe atopic dermatitis. The applicant for this medicinal product is LEO Pharma A/S. Tralokinumab was approved for medical use in the European Union in June 2021. Names
Tralokinumab is the international nonproprietary name (INN) and the United States Adopted Name (USAN). References
External links
"Tralokinumab". Drug Information Portal. U.S. National Library of Medicine.